TITLE

Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas

AUTHOR(S)
Weidmann, E.; Neumann, A.; Fauth, F.; Atmaca, A.; Al-Batran, S. E.; Pauligk, C.; Jäger, E.
PUB. DATE
August 2011
SOURCE
Annals of Oncology;Aug2011, Vol. 22 Issue 8, p1839
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: Rituximab plus combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) is widely recommended for the treatment of aggressive B-cell lymphomas. However, there is very little information regarding the management of elderly patients.Patients and methods: We initiated a phase II study of first-line treatment with rituximab and bendamustine in elderly patients (≥80 years) with aggressive B-cell lymphomas who were not eligible for R-CHOP or who did not agree to aggressive treatment. The treatment decision on eligibility for R-CHOP was left to discretion of the physicians.Results: Fourteen patients with a median age of 85 years (range 80–95 years) were included. The age-adjusted international prognostic index was zero in five patients, one in three patients, and two in six patients. Thirteen patients were assessable for response. Seven patients (54%) had a complete response, two (15%) a partial response, and four (31%) progressive disease. The median overall survival was 7.7 months, and the median progression-free survival 7.7 months; however, six patients (43%) were alive without disease at 20–72 months from the start of treatment. Major toxicity was neutropenia (17% grade 3 and 6% grade 4). All other grade 3 and 4 hematotoxicities and non-hematological toxic effects ranged between 2% and 11%Conclusions: Because of its efficacy and low toxicity, bendamustine in combination with rituximab may be an alternative treatment for aggressive lymphomas in old patients not eligible for R-CHOP. These results, however, need to be confirmed in larger studies.
ACCESSION #
63715412

 

Related Articles

  • Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Ketterer, N.; Coiffier, B.; Thieblemont, C.; Fermé, C.; Brière, J.; Casasnovas, O.; Bologna, S.; Christian, B.; Connerotte, T.; Récher, C.; Bordessoule, D.; Fruchart, C.; Delarue, R.; Bonnet, C.; Morschhauser, F.; Anglaret, B.; Soussain, C.; Fabiani, B.; Tilly, H.; Haioun, C. // Annals of Oncology;Apr2013, Vol. 24 Issue 4, p1032 

    Background The superiority of a chemotherapy with doxorubicin, cyclophosphamide, vindesine, bleomycin and prednisone (ACVBP) in comparison with cyclophosphamide, doxorubicin, vincristin and prednisone plus radiotherapy for young patients with localized diffuse large B-cell lymphoma (DLBCL) was...

  • The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab. Meyer, Paul N.; Kai Fu; Greiner, Timothy; Smith, Lynette; Delabie, Jan; Gascoyne, Randy; Ott, German; Rosenwald, Andreas; Braziel, Rita; Campo, Elias; Vose, Julie; Lenz, Georg; Staudt, Louis; Chan, Wing; Weisenburger, Dennis D. // American Journal of Clinical Pathology;Jan2011, Vol. 135 Issue 1, p54 

    The cellular composition of the tumor microenvironment may affect survival in diffuse large B-cell lymphoma (DLBCL). We performed immunostains for 2 stromal cell markers, CD68 and SPARC (secreted protein, acidic and rich in cysteine), in 262 patients with DLBCL treated with rituximab and...

  • Primary cutaneous large B-cell lymphoma, leg type. Thomas, Vibha; Dobson, Robin; Mennel, Robert // Baylor University Medical Center Proceedings;Oct2011, Vol. 24 Issue 4, p350 

    Primary cutaneous large B-cell lymphoma, leg type, is a rare and aggressive neoplasm as defined by the recently updated World Health Organization-European Organization for Research and Treatment of Cancer classification of cutaneous lymphomas. We present a case of a 74-year-old woman who...

  • Treatment Strategies for Diffuse Large B Cell Lymphoma. Thieblemont, Catherine; Gisselbrecht, Christian // Current Medical Literature: Leukemia & Lymphoma;2010, Vol. 18 Issue 3, p57 

    The article discusses treatments for diffuse large B cell lymphoma (DLBCL). Considered as the most usual form of adult non-Hodgkin lymphoma (NHL), first line treatment for the disease is the combination therapy rituximab with cyclophosphamide, vincristine, doxorubicin and prednisone (R-CHOP)....

  • Interim PET/CT-based prognostic model for the treatment of diffuse large B cell lymphoma in the post-rituximab era. Yang, Deok-Hwan; Ahn, Jae-Sook; Byun, Byung; Min, Jung; Kweon, Sun-Seog; Chae, Yee; Sohn, Sang; Lee, Sang; Kim, Hae; Jung, Sung-Hoon; Kim, Yeo-Kyeoung; Kim, Hyeoung-Joon; Bom, Hee-Seung; Lee, Je-Jung // Annals of Hematology;Apr2013, Vol. 92 Issue 4, p471 

    The prognostic accuracy of interim F-fluoro-2-dexoy- d-glucose positron emission tomography/computerized tomography (PET/CT) using three different methods of response assessments during rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy was investigated in 186...

  • A study on nm23-H1 expression in diffuse large B-cell lymphoma that was treated with CyclOBEAP plus rituximab therapy. Niitsu, Nozomi; Tamaru, Jun-ichi; Yoshino, Tadashi; Nakamura, Naoya; Nakamura, Shigeo; Ohshima, Kohichi; Nakamine, Hirokazu; Okamoto, Masataka // Annals of Hematology;Feb2011, Vol. 90 Issue 2, p185 

    In our previous study on nm23-H1 expression with diffuse large B-cell lymphoma (DLBCL), we found that patients with positive nm23-H1 had significantly poorer prognosis than patients with negative nm23-H1. We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab era. The...

  • The diffuse large B-cell lymphoma - where do we stand now in everyday clinical practice. Gregoric, Brigita; Zadnik, Vesna; Novakovic, Barbara Jezersek // Radiology & Oncology;2012, Vol. 46 Issue 2, p153 

    Background. Due to superior results observed with the addition of rituximab into treatment of patients with the diffuse large B-cell lymphoma (DLBCL),the R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) regimen and its variants became the standard initial...

  • Primary renal lymphoma—a case report. Geetha, N.; Shahid, Abdul; Rajan, Varun; Jacob, Priya Mary // Ecancermedicalscience;2014, Vol. 8 Issue 447-473, p1 

    Primary renal lymphoma is a rare entity representing less than 1% of lesions in the kidney. We present the case of a 42-year-old male who was evaluated for pain and a mass in the abdomen. The computed tomogram of the abdomen showed a large lobulated homogeneously enhancing mass lesion of about...

  • The comparison between CHOP and R-CHOP in primary gastric diffuse large B cell lymphoma. Sohn, Byeong; Kim, Sun-Mok; Yoon, Dok; Kim, Shin; Lee, Dae; Kim, Jin-Ho; Lee, Sang-Wook; Huh, Jooryung; Suh, Cheolwon // Annals of Hematology;Nov2012, Vol. 91 Issue 11, p1731 

    The combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) plus rituximab is the standard treatment for patients with primary gastric diffuse large B cell lymphoma (DLBCL). However, a few trials comparing CHOP plus rituximab (R-CHOP) with CHOP have been...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics